US20130259870A1 - Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease - Google Patents

Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease Download PDF

Info

Publication number
US20130259870A1
US20130259870A1 US13/573,436 US201213573436A US2013259870A1 US 20130259870 A1 US20130259870 A1 US 20130259870A1 US 201213573436 A US201213573436 A US 201213573436A US 2013259870 A1 US2013259870 A1 US 2013259870A1
Authority
US
United States
Prior art keywords
liver
nonalcoholic steatohepatitis
reduction
galactomannan polysaccharide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/573,436
Other languages
English (en)
Inventor
Peter G. Traber
Eliezer Zomer
Anatole A. Klyosov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galectin Therapeutics Inc
Original Assignee
Galectin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Therapeutics Inc filed Critical Galectin Therapeutics Inc
Priority to US13/573,436 priority Critical patent/US20130259870A1/en
Assigned to GALECTIN THERAPEUTICS, INC. reassignment GALECTIN THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KLYOSOV, ANATOLE A., TRABER, PETER G., ZOMER, ELIEZER
Publication of US20130259870A1 publication Critical patent/US20130259870A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0045—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof

Definitions

  • Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis are common liver disorders in the United States. Histopathologically, these disorders resemble alcoholic liver disease, but they occur in people who drink little or no alcohol.
  • the pathological changes in the liver include, but are not limited to, fat accumulation in hepatocytes, evidence of hepatocellular degeneration, infiltrates of inflammatory cells, deposition of excess fibrous tissue, hepatocellular nodule formation, cirrhosis, and hepatocellular carcinoma. To date, no specific therapies for these disorders exist. Therefore, there is a need to provide methods for treatment of nonalcoholic steatohepatitis with or without associated liver fibrosis.
  • aspects of the invention relate to methods of treating a subject having a fatty liver, nonalcoholic fatty liver disease (NALFD), nonalcoholic steatohepatitis (NASH), nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepatitis with cirrhosis, or nonalcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma, using a therapeutic composition comprising a galactose-containing polysaccharide compound in an acceptable pharmaceutical carrier for parenteral or enteral administration.
  • NALFD nonalcoholic fatty liver disease
  • NASH nonalcoholic steatohepatitis
  • nonalcoholic steatohepatitis with liver fibrosis nonalcoholic steatohepatitis with cirrhosis
  • nonalcoholic steatohepatitis with cirrhosis and hepatocellular carcinoma using a therapeutic composition comprising a galactose-containing polysaccharide compound in an acceptable pharmaceutical carrier for parenteral
  • the invention relate to compositions having a galactomannan polysaccharide for the treatment of fatty liver, NALFD, NASH, NASH with liver fibrosis, NASH with cirrhosis, or NASH with cirrhosis and hepatocellular carcinoma.
  • Other aspects of the invention relate to the use of a galactomannan polysaccharide in the manufacture of a pharmaceutical composition for the treatment of fatty liver, NALFD, NASH, NASH with liver fibrosis, NASH with cirrhosis, or NASH with cirrhosis and hepatocellular carcinoma.
  • an admixture having a galactomannan polysaccharide and a therapeutic agent can be used for the treatment or in the manufacture of a pharmaceutical composition for treatment of fatty liver, NALFD, NASH, NASH with liver fibrosis, NASH with cirrhosis, or NASH with cirrhosis and hepatocellular carcinoma.
  • the method comprises the steps of obtaining a composition for parenteral or enteral administration comprising a galactomannan polysaccharide compound in an acceptable pharmaceutical carrier; administering to a subject an effective dose of the composition for parenteral administration, the subject having one of a fatty liver, NALFD, NASH, NASH with liver fibrosis, NASH with cirrhosis, or NASH with cirrhosis and hepatocellular carcinoma.
  • the effective dose of the composition when administered in a subject in need thereof, can result in reduction of at least one point in severity of NALFD or NASH grading scoring systems, reduction of the level of serum markers of NASH activity, reduction of NASH disease activity or reduction in the medical consequences of NASH.
  • the efficacy of the composition for parenteral administration can be determined by administering the composition to animal models of NASH, including but not limited, to mice rendered diabetic and fed a high fat diet, resulting in at least 5% reduction in hepatocellular fat accumulation, at least 5% reduction in liver infiltration of inflammatory cells, or at least a 5% reduction in liver collagen content as determined by morphometric quantification.
  • the effective dose of the composition when administered in a subject in need thereof, can result in the reduction in the accumulation of fat in the liver (steatosis) as determined from liver histological sections by assessment of micro-vesicular and macro-vasicular fat particles in hepatocytes.
  • the accumulation of fat in the liver is reduced by at least 10% as assessed in percentage of hepatocytes with fat and graded as per NAFLD grading system or by image analysis.
  • the effective dose of the composition when administered in a subject in need thereof, can result in the reduction of hepatocyte ballooning as determined from liver histological section by assessment of swelling of hepatocytes indicating toxicity and inability to regulate cellular volume.
  • the hepatocyte ballooning is reduced by at least 10% as assessed in percentage of swollen hepatocytes and graded as per NAFLD grading system.
  • the effective dose of the composition when administered in a subject in need thereof, can result in the reduction in the infiltration of inflammatory cells in liver histological specimens as assessed by the number of neutrophils and lymphocytes in portal, central and lobular areas of the liver specimens.
  • the infiltration of inflammatory cells in liver histological specimens is reduced by at least 10% less as assessed in percentage of inflammatory cells graded using the NAFLD grading system.
  • the effective dose of the composition when administered in a subject in need thereof, can result in the reduction in the level of serum markers of NASH activity.
  • the serum markers of NASH activity can include, but are not limited to, serum levels of transaminases, serum levels of coenzyme Q reduced or oxidized, or a combination of other serum markers of NASH activity known in the art.
  • the effective dose of the composition when administered in a subject in need thereof, can result in the reduction of liver fibrosis or cirrhosis based on evidence comprising a reduction of the level of the biochemical markers of fibrosis, non invasive testing of liver fibrosis or cirrhosis or liver histologic grading of fibrosis or cirrhosis.
  • the effective dose of the composition when administered in a subject in need thereof, can result in the reduction of at least one point in severity of NAFLD or NASH grading scoring systems, including but not limited to, NAFLD activity score (NAS), proposed by the NASH Clinical Research Network (established in 2002 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)), a widely used scoring system.
  • NAFLD activity score NAS
  • NASH Clinical Research Network established in 2002 by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • NIDDK National Institute of Diabetes and Digestive and Kidney Diseases
  • the effective dose of the composition when administered in a subject in need thereof, can result in the reduction in the medical consequences of NASH with liver fibrosis or cirrhosis comprising portal hypertension, reduced hepatic protein synthesis, hyperbilirubinemia, or encephalopathy.
  • the effective dose of the composition when administered in a subject in need thereof, can result in the reduction in disease activity based on at least a 10% reduction in liver tissue or serum galectin-3.
  • the effective dose of the composition when administered in a subject in need thereof, can result in the reduction of accumulation of collagen in the liver as determined by quantitative analysis of Sirius Red staining of liver histological sections. In some embodiments, the reduction of accumulation of collagen in the liver is reduced by at least 5% less as assessed in percentage of liver tissue staining positive for Sirius red indicating collagen.
  • the galactomannan polysaccharide consists essentially of galactose and mannose residues and resulting from a sufficiently controlled depolymerization of galactomannan so as to result in a galactomannan polysaccharide composition with a defined average molecular weight.
  • the galactomannan polysaccharide compound consists essentially of galactose and mannose residues and resulting from a sufficiently controlled depolymerization of galactomannan so as to result in a homogenous galactomannan polysaccharide has an average weight of 4,000 to 60,000 D as assayed by GPC-MALLS.
  • the galactomannan polysaccharide compound has a ratio of mannose to galactose molecules in a range of 1:1 to 1:4.
  • the galactomannan polysaccharide compound has a ratio of mannose to galactose molecules of 1.7:1.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of cysteamine or a pharmaceutically acceptable salt thereof, or cystamine or a pharmaceutically acceptable salt thereof.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of various anti-oxidant compounds including but not limited to parenteral or oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of various anti-oxidant compounds including but not limited to parenteral or oral administration of compositions comprising a water soluble Vitamin E preparation, mixed carotenoids, or selenium.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of parenteral or oral administration of lecithin or vitamin B complex.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of bile salt preparations including but not limited to ursodeoxycholic acid, chenodeoxycholic acid of other naturally occurring or synthetic bile acids or bile acid salts.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor.
  • CB1 Cannabinoid-1
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of a PPAR (peroxisome proliferator-activated receptor) activity regulator.
  • PPAR peroxisome proliferator-activated receptor
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of a benzothiazepine or benzothiepine compound having a thioamide bond and a quaternary ammonium substituent.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of an RNA antisense construct to inhibit protein tyrosine phosphatase PTPRU.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of a heteroatom-linked substituted piperidine and derivatives thereof useful as histamine H.sub.3 antagonists.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of a axacyclopentane derivative that inhibits stearoyl-coenzyme alpha delta-9 desaturase.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of a acylamide compound having secretagogue or inducer activity of adiponectin.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of quaternary ammonium compounds.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of a isoflavone compound.
  • the compound is a galactomannan polysaccharide composition used in combination with a therapeutically effective amount of a macrolide antibiotic.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of Glatiramer acetate (also known as Copolymer 1, Cop-1, or Copaxone—as marketed by Teva Pharmaceuticals), an immunomodulator drug currently used to treat multiple sclerosis.
  • Glatiramer acetate also known as Copolymer 1, Cop-1, or Copaxone—as marketed by Teva Pharmaceuticals
  • an immunomodulator drug currently used to treat multiple sclerosis.
  • the compound is galactomannan polysaccharide used in combination with a therapeutically effective amount of a stain, for example but not limited to HMG-CoA reductase inhibitors such as atorvastatin and simvastatin.
  • a stain for example but not limited to HMG-CoA reductase inhibitors such as atorvastatin and simvastatin.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of an n-acetyl cysteine.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of another galectin inhibitor that may inhibit single galectin proteins or a set of galectin proteins including but not limited small organic inhibitors of galectin, monoclonal antibodies, RNA inhibitors, small binding peptides, or protein inhibitors or any combinations of the foregoing.
  • the compound is a used in combination with a therapeutically effective amount of a monoclonal antibody to inhibit lysyl oxidase (or other proteins that cross link collagens) or monoclonal antibody to connective tissue growth factor.
  • FIG. 1 is a schematical representation of the Experimental Design of Therapy in STAM Mouse Model of Steatohepatitis
  • FIG. 2A is a graph showing the changes in body weight of STAM mice in treatment groups at weeks 6-9.
  • FIG. 2B is a graph showing the changes in body weight of STAM mice in treatment groups at weeks 9-12.
  • FIG. 3A is a graph showing the whole blood glucose in STAM mice between the treatment groups at weeks 6-9.
  • FIG. 3B is a graph showing the whole blood glucose in STAM mice between the treatment groups at weeks 9-12.
  • FIG. 4 shows the histology of the normal and the NASH mouse model stained with hematoxylin and eosin (H&E) and with Sirius Red.
  • FIG. 5A shows the histology comparison of STAM mice between the treatment groups.
  • FIG. 5B is a graph showing the NAFLD activity score in STAM mice in the treatment groups.
  • FIG. 5C is a graph showing the steatosis grade score in STAM mice in the treatment groups.
  • FIG. 6 shows the liver histology with Sirius red staining of experimental groups at weeks 6-9 and 9-12.
  • FIG. 7A is a graph showing the comparison of Sirius red-positive area in liver histology between experimental groups at weeks 6-9.
  • FIG. 7B is a graph showing the comparison of Sirius red-positive area in liver histology between experimental groups at weeks 9-12.
  • FIG. 7C is a graph showing the comparison of Sirius red-positive area in liver histology between experimental groups for all animals
  • FIG. 8A shows the immunohistochemical staining of alpha-Smooth Muscle Actin (SMA) in liver tissue of experimental groups.
  • FIG. 8B is a graph showing the digital morphometry of alpha-Smooth Muscle Actin (SMA) in liver tissue of experimental groups.
  • FIG. 9A shows the immunohistochemical staining of galectin-3 in liver tissue of experimental groups.
  • FIG. 9B is a graph showing the digital morphometry of galectin-3 in liver tissue of experimental groups.
  • Nonalcoholic Fatty Liver Disease is fat accumulation in hepatocytes with minimal inflammation. These patients are usually identified on the basis of a liver biopsy performed because of mildly elevated liver transaminase levels in the serum or the suspicion of fatty liver on non-invasive testing such as computerized tomography or ultrasound.
  • NASH Nonalcoholic Steatohepatitis
  • inflammatory cells including but not limited to neutrophils or lymphocytes
  • This inflammatory state of NASH may result in the deposition of fibrous tissue, including but not limited to collagen, which can lead to cirrhosis, nodule formation, and eventually hepatocellular carcinoma.
  • NAFLD and NASH are common disorders. It is reported by the U.S. National Institutes of Health that 10-20 percent of Americans have NAFLD and 3-5 percent have NASH. Both are becoming more common because of the greater numbers of people with obesity and diabetes, including children and adolescents. The fact that NASH can progress to cirrhosis makes this a major health problem.
  • NASH has become more common, its underlying cause is still not clear. It most often occurs in middle-aged persons who overweight or obese, many of whom have metabolic syndrome, insulin resistance, or overt diabetes. However, NASH is not simply obesity that affects the liver. NASH can affect children and adolescents.
  • liver injury in NASH is not known. Multiple theories have been proposed, with some experimental data to suggest their involvement. Some of these include, but are not limited to, hepatocyte resistance to the action of insulin, production of inflammatory cytokines by fat cells and other inflammatory cells that damage the liver and recruit additional inflammatory cells and oxidative stress in hepatocytes with production of reactive oxygen radicals that damage liver cells and induce inflammation.
  • Galectins also known as galaptins or S-lectin
  • S-lectin are a family of lectins which bind beta-galactoside.
  • Galectin as general name was proposed in 1994 for a family of animal lectins (Barondes, S. H., et al.: Galectins: a family of animal b-galactoside-binding lectins. Cell 76, 597-598, 1994), The family is defined by having at least one characteristic carbohydrate recognition domain (CRD) with an affinity for beta-galactosides and sharing certain sequence elements.
  • CCD characteristic carbohydrate recognition domain
  • galectins within the same peptide chain, some galectins have a CRD with only a few additional amino acids, whereas others have two CRDs joined by a link peptide, and one (galectin-3) has one CRD joined to a different type of domain.
  • the galectin carbohydrate recognition domain is a beta-sandwich of about 135 amino acids. The two sheets are slightly bent with 6 strands forming the concave side and 5 strands forming the convex side. The concave side forms a groove in which carbohydrate is bound (Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F (2004). “Introduction to galectins”. Glycoconj. J. 19 (7-9): 433-40).
  • galectins A wide variety of biological phenomena have been shown to be related to galectins, e.g., development, differentiation, morphogenesis, tumor metastasis, apoptosis, RNA splicing, etc. However, relatively little is known about the mechanism by which galectins exert these functions, particularly in terms of carbohydrate recognition.
  • carbohydrate domain binds to galactose residues associated with glycoproteins.
  • At least fifteen mammalian galectin proteins have been identified which have one or two carbohydrate domain in tandem.
  • Each galectin protein has a galactose binding domain and other domains that allow homo- or hetero-dimerization to other galectin proteins.
  • Galectin proteins are expressed in a broad range of cells and tissues at low levels under physiological conditions and are found in the nucleus, cytoplasm, and are secreted into the extracellular space by a non-traditional secretory pathway.
  • the galactose binding domain of galectins binds to galactose containing glycoproteins located on the cell surface or on extracellular matrix proteins.
  • the dimerization domains on galectins promote interaction of galectin proteins, thereby creating interaction between membrane or matrix glycoproteins. These interactions promote cell-cell, cell-matrix, and matrix-matrix interactions and association of membrane receptors that can cause activation, inactivation, or modulation of cell receptor activity leading to modulation of intracellular signaling and subsequent events.
  • galectin molecules are markedly up-regulated and secreted in high amounts from cells in pathological situations.
  • Multiple inflammatory cells including but not limited to macrophages and lymphocytes, in tissue inflammation states and repair (fibrosis, scarring) express galectins, particularly galectin-1 and galectin-3.
  • mice that lack the galectin-3 gene have been used to explore the function of galectin-3 in a number of disease states that include inflammation and fibrogenesis as key components. These galectin-3 knockout mice have been shown to be resistant to liver fibrogenesis due to toxin administration, lung fibrogenesis, and kidney fibrogenesis.
  • Galectin-3 knockout mice have also been used to explore the importance of galectin-3 in NASH.
  • mice were fed a high fat diet to induce the development of NAFLD and NASH.
  • Normal mice readily developed fatty liver, inflammatory infiltrates in the liver and liver fibrosis.
  • the galectin-3 knockout mice did not develop as much fatty liver, and had minimal inflammatory infiltrate and fibrosis.
  • Inhibition of galectin-3 is one potential mechanism underlying the efficacy of galactomannan oligosaccharide compositions in this invention.
  • a therapeutically effective dose means the amount of galactomannan oligosaccharide or other agent in combination with the galactomannan oligosaccharide composition that, when administered as a parental dose or in an oral formulation to an animal or human with NAFLD, NASH, or NASH with fibrosis or cirrhosis, is capable of improving NAS score by at least one point or reducing percent collagen area by at least 5%.
  • a therapeutically effective dose can be evaluated by a reduction of at least 10% in the level of galectin-3 in liver tissue or serum.
  • a therapeutically effective dose can be evaluated by a change in the level of galectin-3 in serum.
  • pharmaceutically acceptable carrier refers to any and all solvents, dispersion media, e.g., human albumin or cross-linked gelatin polypeptides, coatings, antibacterial and antifungal compounds, isotonic, e.g., sodium chloride or sodium glutamate, and absorption delaying compounds, and the like that are physiologically compatible.
  • the carrier is suitable for oral, intravenous, intramuscular, subcutaneous, parenteral, spinal or epidural administration (e.g., by injection or infusion).
  • the active compound can be coated in a material to protect the compound from the action of acids and other natural conditions that can inactivate the compound.
  • efficacy means demonstrating an improvement in the liver histology findings associated with NASH or NASH with fibrosis or cirrhosis as determined by the NAS score or percent collagen.
  • the method comprises the steps of obtaining a composition for parenteral or enteral administration comprising a galactomannan polysaccharide compound in an acceptable pharmaceutical carrier.
  • the compound is a galactomannan oligosaccharide consisting essentially of galactose and mannose residues and resulting from a sufficiently controlled depolymerization of galactomannan so as to result in a galactomannan polysaccharide composition with a defined average molecular weight.
  • “depolymerization” refers to partial or complete hydrolysis of the polysaccharide backbone occurring for example when the polysaccharide is treated chemically and resulting in fragments of reduced size when compared with the original polysaccharide.
  • Galactomannan can be obtained from a variety of natural sources such as plants and microbial sources.
  • the polysaccharide can also be synthetically made.
  • Galactomannan can be derived from carob gum ( Ceratonia siliqua ), guar gum ( Cyamopsis tetragonoloba ), and honey locust ( Gleditsia triacanthos ), are examples of commercial available galactomannans.
  • the polysaccharides include, but are not limited to, galactomannans available from a number of plant and microbial sources.
  • the galactomannan can be a derivative of Guar gum from seeds of Cyamopsis tetragonoloba .
  • the galactomannan can be a derivative of Gleditsia triacanthos, medicago falcate, Trigonella Foenum - graecum and microbial like Ceratonia siliqua Xanthomonas campestris , yeast and mold galactomannan, Arabinogalactan (from Larix occidentalis ), Rhamnogalacturonan (from potato), Carrageenan (from Eucheuma Seaweed), and the Locust Bean Gum (from Ceratonia siliqua.
  • backbone means the major chain of a polysaccharide, or the chain originating from the major chain of a starting polysaccharide, having saccharide moieties sequentially linked by either .alpha or .beta glycosidic bonds.
  • a backbone may comprise additional monosaccharide moieties connected thereto at various positions along the sequential chain.
  • the galactomannan polysaccharide composition consists essentially of galactose and mannose residues and resulting from a sufficiently controlled depolymerization of galactomannan so as to result in a homogenous galactomannan polysaccharide.
  • the galactomannan polysaccharide has an average weight of 4,000 to 60,000 D, as assayed by GPC-MALLS (galactomannan).
  • the galactomannan polysaccharide composition has a ratio of mannose to galactose molecules in a range of 1:1 to 1:4.
  • the galactomannan polysaccharide composition has a ratio of mannose to galactose molecules of 1.7.
  • the galactomannan polysaccharide composition is produced as described in U.S. Pat. No. 7,893,252 incorporated expressly by reference in its entirety for all purposes.
  • the process is designed to generate a highly pure soluble and homogeneous oligomer with an average molecular weight in the range of about 48,000 daltons, and mannose to galactose ratio in the range of about 1.7:1.
  • the process incorporates four major phases: controlled depolymerization to produce the desired galactomannan oligomer and three purification steps, removal of insoluble impurities, removal of water soluble impurities, removal of organic soluble impurities, and finally freeze drying to generate a pure and stable form of galactomannan powder.
  • the product is in the form of a highly soluble oligomer of Galactomannan (GM).
  • Galactomannan can be packaged and delivered as a sterile concentrated solution in a single use vial, while bulk galactomannan can be produced and stored as powder.
  • the process described herein is for both bulk drug and final drug product.
  • the galactomannan drug product can be combined and administered together with a therapeutically effective amount of a therapeutic agent to form the active ingredients of a pharmaceutical preparation.
  • the drug product can contain normal saline for infusion (about 0.9 M sodium chloride in water) and has a pH of about 6.5.
  • the compound is a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of a therapeutic agent.
  • the galactomannan polysaccharide can be used in admixture.
  • “Admixture” means more than one component mixed together to form a combination.
  • “admixture” means the mixture of two or more compounds at any time prior or subsequent to, or concomitant with, administration.
  • the therapeutic agent can be cysteamine or a pharmaceutically acceptable salt thereof, or cystamine or a pharmaceutically acceptable salt thereof.
  • the compound is a galactomannan polysaccharide composition
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of various anti-oxidant compounds including but not limited to parenteral or oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol.
  • parenteral or oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol.
  • the compound is a galactomannan polysaccharide composition
  • a therapeutically effective amount of various anti-oxidant compounds including but not limited to parenteral or oral administration of compositions comprising a water soluble Vitamin E preparation, mixed carotenoids, or selenium [U.S. Pat. No. 6,596,762, incorporated expressly by reference for all purposes.]
  • the compound is a galactomannan polysaccharide composition
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of parenteral or oral administration of lecithin or vitamin B complex [U.S. Pat. Nos. 7,018,652; 6,180,139, incorporated expressly by reference for all purposes.]
  • the compound is a galactomannan polysaccharide composition
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of bile salt preparations including but not limited to ursodeoxycholic acid, chenodeoxycholic acid of other naturally occurring or synthetic bile acids or bile acid salts.
  • bile salt preparations including but not limited to ursodeoxycholic acid, chenodeoxycholic acid of other naturally occurring or synthetic bile acids or bile acid salts.
  • the compound is a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor.
  • CB1 Cannabinoid-1
  • the compound is a galactomannan polysaccharide composition
  • a PPAR peroxisome proliferator-activated receptor activity regulators
  • the compound is a galactomannan polysaccharide composition
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of a benzothiazepine or benzothiepine compound represented by the following formula having a thioamide bond and a quaternary ammonium substituent.
  • a benzothiazepine or benzothiepine compound represented by the following formula having a thioamide bond and a quaternary ammonium substituent.
  • the compound is a galactomannan polysaccharide composition
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of an RNA antisense construct to inhibit protein tyrosine phosphatase PTPRU.
  • an RNA antisense construct to inhibit protein tyrosine phosphatase PTPRU.
  • the compound is a galactomannan polysaccharide composition
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of a heteroatom-linked substituted piperidine and derivatives thereof useful as histamine H.sub.3 antagonists.
  • a heteroatom-linked substituted piperidine and derivatives thereof useful as histamine H.sub.3 antagonists.
  • the compound is a galactomannan polysaccharide composition
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of a axacyclopentane derivative that inhibits stearoyl-coenzyme alpha delta-9 desaturase.
  • a axacyclopentane derivative that inhibits stearoyl-coenzyme alpha delta-9 desaturase.
  • the compound is a galactomannan polysaccharide composition
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of a acylamide compound having secretagogue or inducer activity of adiponectin.
  • the compound is a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of quaternary ammonium compounds.
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of quaternary ammonium compounds.
  • the compound is a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of a isoflavone compound.
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of a isoflavone compound.
  • the compound is a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of a macrolide antibiotic.
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of a macrolide antibiotic.
  • the compound is a galactomannan polysaccharide composition
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of Glatiramer acetate (also known as Copolymer 1, Cop-1, or Copaxone—as marketed by Teva Pharmaceuticals), an immunomodulator drug currently used to treat multiple sclerosis.
  • Glatiramer acetate also known as Copolymer 1, Cop-1, or Copaxone—as marketed by Teva Pharmaceuticals
  • an immunomodulator drug currently used to treat multiple sclerosis.
  • the compound is a galactomannan polysaccharide used in combination with a therapeutically effective amount of pentraxin proteins, including but not limited to recombinant pentraxin-2.
  • the compound is a galactomannan polysaccharide composition
  • a stain for example but not limited to HMG-CoA reductase inhibitors such as atorvastatin and simvastatin.
  • the compound is a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of an n-acetyl cysteine.
  • the compound is a galactomannan polysaccharide composition
  • a therapeutically effective amount of another galectin inhibitor that may inhibit single galectin proteins or a set of galectin proteins, including but not limited to, small organic inhibitors of galectin, monoclonal antibodies, RNA inhibitors, small binding peptides, protein inhibitors or combinations thereof.
  • the compound is a galactomannan polysaccharide composition
  • a galactomannan polysaccharide composition can be used in combination with a therapeutically effective amount of a monoclonal antibody to inhibit lysyl oxidase (or other proteins that cross link collagens) or monoclonal antibody to connective tissue growth factor.
  • the compound comprises molecules which have a first portion, which is typically a carbohydrate, and which is capable of binding to galectins, joined to a second portion which inactivates or otherwise moderates the activity of a protein.
  • This second portion need not be a carbohydrate and can comprise a material which cross links or otherwise denatures the segment of protein comprising an active portion of the galectin protein, or an active portion of another protein which interacts with the galectin.
  • Such materials include active species such as sulfur or other chalcogen elements alone or in combination such as thiols, sulfhydryls and the like.
  • Other active species may comprise cyano groups, thiocyanates, alkylating agents, aldehydes and the like.
  • a NASH therapeutic formulation with suitable or increased efficacy in the treatment of NASH or NALD includes and effective dose of the galactomannan polysaccharide compound or composition.
  • the NASH therapeutic formulation can be administered alone or co-administered with an effective dose of a therapeutic agent in a mixture or regimen.
  • the formulation my further include an additional NASH therapeutic agent or excipients in which the formulation is in a powder form or in a liquid form.
  • an effective dose of the galactomannan polysaccharide composition can be administered in a formulation for oral administration.
  • the formulation may include methods of physical alterations of the compound or additions of various agents that enhance the oral absorption of the galactose-containing polysaccharide.
  • the galactomannan polysaccharide composition and other compounds described are proposed as therapy alone or in combination with other compounds listed above, for human NASH as a method of ameliorating or reversing hepatocyte fat accumulation, intra-portal and intra-lobular inflammatory infiltrate, and fibrosis, including but not limited to collagen deposition in the peri-sinusoidal space, cirrhosis, and for preventing progression to hepatocellular carcinoma.
  • these improvements in liver disease pathology will have a resultant positive effect on the health of the individuals by reducing complications of liver fibrosis and cirrhosis, including the development of hepatocellular carcinoma.
  • an effective dose of the galactomannan polysaccharide composition can be administered via a variety of routes including, parenteral via an intravenous infusion given as repeated bolus infusions or constant infusion, intradermal injection, subcutaneously given as repeated bolus injection or constant infusion, or oral administration.
  • An effective parental dose (given intravenously, intraperitoneally, or subcutaneously) of galactose containing polysaccharide to an experimental animal is within the range of 10 mg/kg up to 180 mg/kg body weight, or 10 mg/kg, or 30 mg/kg, or 60 mg/kg, or 120 mg/kg, or 180 mg/kg body weight.
  • An effective parenteral dose (given intravenously, intraperitoneally, or subcutaneously) of the galactomannan oligosaccharide composition to an experimental animal can be administered three times weekly, twice weekly, once weekly, once every two weeks, once monthly, or as a constant infusion.
  • An effective parental dose (given intravenously or subcutaneously) of galactomannan oligosaccharide composition to a human subject is within the range of 0.5 mg/kg up to 25 mg/kg body weight, or 1 mg/kg, or 2 mg/kg, or 5 mg/kg, or 7.5 mg/kg, or 10 mg/kg body weight, or 15 mg/kg body weight.
  • An effective parenteral dose (given intravenously or subcutaneously) of galactose containing polysaccharide to a human subject can be administered three times weekly, twice weekly, once weekly, once every two weeks, once monthly, or as a constant infusion.
  • a therapeutically effective dose can be evaluated by a change of at least 10% in the level of the serum biomarkers of NASH.
  • the serum biomarkers of NASH can include but not limited to hyaluronic acid and other breakdown products of collagens, cytokeratin-18 and other cytoskeletal cellular proteins, tissue inhibitor of metalloprotease I and II and other liver derived collagen and matrix proteases. These compounds and biomarkers may be measured in the serum or in the liver tissue using immunoassays and the levels can be correlated with severity of disease and treatment.
  • a therapeutically effective dose can be evaluated by a change of at least 10% in the level of the serum biomarkers of NASH including but not limited to reactive oxygen products of lipid or protein origin, coenzyme Q reduced or oxidized forms, and lipid molecules or conjugates.
  • serum biomarkers of NASH including but not limited to reactive oxygen products of lipid or protein origin, coenzyme Q reduced or oxidized forms, and lipid molecules or conjugates.
  • biomarkers can be measured by various means including immunoassays and electrophoresis and their levels can be correlated with severity of disease and treatment.
  • a therapeutically effective dose can be evaluated by a change of at least 10% in the level of the serum biomarkers of NASH including but not limited to cytokines that include but are not limited to TNF-alpha, TGF-beta or IL-8, osteopontin, or a metabolic profile of serum components that is indicative of NASH presence or severity (these include serum and urine markers).
  • cytokines that include but are not limited to TNF-alpha, TGF-beta or IL-8, osteopontin, or a metabolic profile of serum components that is indicative of NASH presence or severity (these include serum and urine markers).
  • a profile of one or more of these cytokines as measured by immunoassay or proteomic assessment by LC mass spec, may provide an assessment of activity of the disease and a marker to follow in therapy of the disease.
  • a therapeutically effective dose can be evaluated by a change of at least 10% in the pathophysiologic spectrum of NASH which includes histopathological findings on liver biopsy.
  • Histopathological findings on liver biopsy can include but are not limited to evidence of intra-hepatocellular fat, hepatocellular toxicity including but not limited to hyaline bodies, inflammatory cell infiltrates (including but not limited to lymphocytes and various subsets of lymphocytes and neutrophils), changes in bile duct cells, changes in endothelial cells, number of Kupffer cell macrophages, collagen deposition (including but not limited to peri-sinusoidal, portal and central collagen deposition and portal to central bridging collagen deposition, hepatocellular nodules that distort the normal architecture, hepatocellular atypia consistent with malignant transformation, and various scales and methods that combine various sets of observations for grading the severity of NASH.
  • Such histological assessments are the sine-qua-non of NASH diagnosis and therefore integral
  • a therapeutically effective dose can be evaluated by a change of at least 10% in the clinical manifestations of NASH including but not limited to clinical testing of stage and severity of the disease, clinical signs and symptoms of disease, and medical complications.
  • Clinical testing of stage and severity of NASH include but are not limited to hematologic testing (including but not limited to red blood cell count and morphology, white blood cell count and differential and morphology, platelet count and morphology), serum or plasma lipids including but not limited to triglycerides, cholesterol, fatty acids, lipoprotein species and lipid peroxidation species, serum or plasma enzymes (including but not limited to aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (AP), gamma glutamyltranspeptidase (GGTP), lactate dehydrogenase (LDH) and isoforms, serum or plasma albumin and other proteins indicative of liver synthetic capacity, serum or plasma levels of bilirubin or other compounds indicative
  • Clinical testing also includes but is not limited to non-invasive and invasive testing that assesses the architecture, structural integrity or function of the liver including but not limited to computerized tomography (CT scan), ultrasound (US), ultrasonic elastography (including but not limited to FibroScan) or other measurements of the elasticity of liver tissue, magnetic resonance scanning or spectroscopy, percutaneous or skinny needle or transjugular liver biopsy and histological assessment (including but not limited to staining for different components using affinity dyes or immunohistochemistry), measurement of hepatic portal-venous wedge pressure gradient, or other non-invasive or invasive tests that may be developed for assessing severity of NASH in the liver tissue.
  • CT scan computerized tomography
  • US ultrasound
  • ultrasonic elastography including but not limited to FibroScan
  • histological assessment including but not limited to staining for different components using affinity dyes or immunohistochemistry
  • measurement of hepatic portal-venous wedge pressure gradient or other non-invasive or invasive tests that may be developed for assessing severity of
  • a therapeutically effective dose can be evaluated by a change of at least 10% in clinical signs and symptoms of disease include fatigue, muscle weight loss, spider angiomata, abdominal pain, abdominal swelling, ascites, gastrointestinal bleeding, other bleeding complications, easy bruising and ecchymoses, peripheral edema, hepatomegaly, nodular firm liver, somnolence, sleep disturbance, and coma.
  • Medical complications of NASH are related to cirrhosis and include ascites, peripheral edema, esophageal and other gastrointestinal tract varices, gastrointestinal bleeding, other bleeding complications, emaciation and muscle wasting, hepatorenal syndrome, and hepatic encephalopathy.
  • An additional complication of NASH related cirrhosis is the development of complications sufficiently severe to warrant placement on liver transplantation list or receiving a liver transplantation.
  • a therapeutically effective dose has an effect on NASH liver disease and/or fibrosis in the absence of any effect on whole blood glucose in patients with diabetes or serum lipids in patients with elevated serum lipids.
  • the galactomannan oligosaccharide composition produced has been labeled GM-CT-01 in this application.
  • a purification and manufacturing process for a galactomannan compound is described.
  • High grade Guar gum was dissolved in warm water at 1% at 45° C. for 2 hr.
  • the pH is reduced to 2.2 with 1M HCl and solution was heated to 95° C. for 2 hours.
  • pH is adjusted to 5.8 with 1 M NaOH.
  • the solution was then cooled to 20° C. and filtered with glass filter.
  • CuSO4/Na—K tartrate was added and the precipitate was collected on 200 mesh filter, wash with water solution and then washed in 5% HCl in 96% EtOH. It was then washed with 75% EtOH and twice with 96% EtOH, and finally vacuum freeze-dried as white solids.
  • Galactomannan from a readily available source (e.g., Guar gum), was selected for process optimization and manufacturing.
  • the soluble galactomannan oligomer was tested as described in Example 2.
  • the manufacturing process described above produces a product in the form of a highly soluble oligomer of Galactomannan (GM) from certified premium Guar Gum powder (from seeds of Cyamopsis tetragonoloba ).
  • the process is designed to generate a highly pure soluble and homogeneous oligomer with an average molecular weight in the range of about 48,000 daltons (D), and mannose to galactose ratio in the range of about 1:7.
  • the process incorporated four major phases: controlled depolymerization to produce the desired galactomannan oligomer, and three purification steps, removal of insoluble impurities, removal of water soluble impurities, removal of organic soluble impurities, and finally freeze drying to generate a pure and stable form of galactomannan powder.
  • the experimental model used in this example is the mouse in which diabetes was induced and a high fat diet was administered, a model that has been called SIAM mice.
  • diabetes is induced immediately following birth with a single injection of streptozotocin and then four weeks later the mice are started on a high fat diet.
  • This is a proven model in which the mice consistently develop NASH with hepatocyte fat accumulation, evidence of hepatocyte toxicity, portal and lobular inflammatory infiltrates, peri-sinusoidal fibrosis, advanced fibrosis with nodule formation, cirrhosis, and ultimately hepatocellular carcinoma in a certain percentage of animals.
  • the progression of disease appearance is fatty liver (FL) by five weeks of age, steatohepatitis (NASH) by 7 weeks of age, fibrosis (Fib) by 9 weeks of age, nodule formation (N) by 13 weeks of age, and some animals developing hepatocellular carcinoma (HC) by 16 weeks of age ( FIG. 1 ).
  • GM-CT-01 produced as described in Example 1, was given in a dose of 120 mg/kg twice weekly intravenously for four (4) weeks at the each of the starting times indicated. Early treatment was given for weeks 6 through 9 and late therapy was given for weeks 9 through 12.
  • FIG. 2A-2B The changes in body weight of animals sacrificed after the early and late treatment periods are shown in FIG. 2A-2B .
  • FIG. 3 The comparison of whole blood glucose between treatment groups is shown in FIG. 3 .
  • FIGS. 3A-3B shows that the blood glucose levels were markedly elevated in both the vehicle control and GM-CT-01 groups with no statistical differences at either the early or late treatment schedule.
  • the normal blood glucose in mice is approximately 100 mg/dL and the average in the STAM animals was between 700 and 800 mg/dL, hence demonstrating that all animals had overt diabetes.
  • FIG. 4 shows the histology of the liver in normal and NASH mice.
  • Liver sections stained with hematoxylin and eosin (H&E) show a marked difference between the normal liver and NASH liver, with the NASH liver showing large fat filled hepatocytes, ballooning degeneration of hepatocytes and an infiltrate of inflammatory cells.
  • Liver sections stained with Sirius red highlight the presence of type I collagen.
  • FIG. 4 shows very little collagen in the normal liver, but increased collagen localized around central veins and in the peri-sinusoidal space in the NASH liver. This result demonstrates that the pathology of NASH was achieved in this mouse model.
  • the NAFLD activity score is used to evaluate the severity of liver disease on histological sections of liver and gives points for three aspects of NASH pathology including, steatosis (0 ( ⁇ 5%), 1 (5-33%), 2 (33-66%), or 3 (>66%)), hepatocyte ballooning (0 (none), 1, (few), or 3 (many)), and lobular inflammation (0 (no foci), 1 ( ⁇ 2 foci/200 ⁇ field), 2 (2-4 foci/200 ⁇ field), or 3 (>4 foci/200 ⁇ field)).
  • the total number of points is the NAFLD activity score.
  • FIG. 5A shows the histology and FIG. 5B shows the comparison of NFLD activity score on liver histology in SIAM mice between the vehicle and GM-CT-01 treatment groups in the early treatment group.
  • the score for the vehicle treated mice was an average of 5, confirming the presence of NASH. While there was not a statistically significant reduction in the NAFLD activity score in the groups of STAM mice treated with GM-CT-01, there was a statistically significant reduction in steatosis when compared to vehicle animals.
  • FIG. 6 shows the comparison of Sirius red-positive area in liver biopsies of STAM mice between the vehicle and GM-CT-01 treatment group.
  • Sirius red is a histological stain that has a specific affinity for collagen fibers, staining them red, and is therefore a quantitative tool for assessing the degree of fibrosis in liver biopsies.
  • both the early and late treatment groups there is a reduction in Sirius red staining seen in the GM-CT-01 treated animals versus vehicle control.
  • FIG. 7A-B shows that collagen percent area was reduced in the early and late treatment groups, and this difference became statistically significant when both groups were combined ( FIG. 7C ).
  • the data further show that the efficacy of GM-CT-01 has an effect on NASH liver disease and fibrosis in the absence of any effect on whole blood glucose.
  • the blood glucose was not reduced in the treatment groups versus the control groups indicating that the liver disease can be treated without effective treatment of diabetes.
  • FIG. 8A shows immunohistochemical staining for the protein alpha-Smooth Muscle Actin, which is a marker for activated stellate cells.
  • Treatment with GM-CT-01 caused a reduction in alpha-Smooth Muscle Actin which indicates that activated stellate cells are markedly reduced ( FIG. 8B ). This is one of mechanism for the reduced collagen deposition with treatment.
  • FIG. 9A shows immunohistochemical staining of galectin-3 protein in liver tissue of vehicle and GM-CT-01 treated experimental groups. There is high level expression of galectin-3 predominantly in macrophages in the vehicle treated animal. Treatment with GM-CT-01 results in a marked reduction of galectin-3 in the liver associated with improved pathology of the disease ( FIG. 9B ).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US13/573,436 2011-09-16 2012-09-14 Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease Abandoned US20130259870A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/573,436 US20130259870A1 (en) 2011-09-16 2012-09-14 Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535655P 2011-09-16 2011-09-16
US201261656288P 2012-06-06 2012-06-06
US13/573,436 US20130259870A1 (en) 2011-09-16 2012-09-14 Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
US20130259870A1 true US20130259870A1 (en) 2013-10-03

Family

ID=47883762

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/573,436 Abandoned US20130259870A1 (en) 2011-09-16 2012-09-14 Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
US13/573,454 Active US8658787B2 (en) 2011-09-16 2012-09-14 Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/573,454 Active US8658787B2 (en) 2011-09-16 2012-09-14 Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

Country Status (12)

Country Link
US (2) US20130259870A1 (enExample)
EP (1) EP2755480B1 (enExample)
JP (1) JP6185473B2 (enExample)
KR (1) KR101974675B1 (enExample)
CN (1) CN103945695B (enExample)
AU (1) AU2012308491B2 (enExample)
BR (1) BR112014006220A2 (enExample)
CA (1) CA2848711C (enExample)
ES (1) ES2869884T3 (enExample)
IL (1) IL231512B (enExample)
MX (1) MX360979B (enExample)
WO (2) WO2013040316A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160243152A1 (en) * 2013-09-19 2016-08-25 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US10695363B2 (en) 2017-04-14 2020-06-30 Gelesis Llc Compositions and methods for treating or preventing gut permeability-related disorders

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
KR101968370B1 (ko) 2011-12-28 2019-04-11 갈렉틴 테라퓨틱스, 인크. 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물
ES2848538T3 (es) 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
BR112015005772A2 (pt) * 2012-09-17 2017-08-08 Galectin Therapeutics Inc método para a intensificação de imunoterapias específicas no tratamento de câncer
US20170014446A1 (en) * 2014-03-10 2017-01-19 La Jolla Pharmaceutical Company Compositions and methods for administering galectin antagonists
JP2017525702A (ja) * 2014-08-18 2017-09-07 ファーマジェネシス， インコーポレイテッド ポリガラクツロナンラムノガラクツロナン（ｐｇｒｇ１）組成物
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
BR112017018882A2 (pt) * 2015-03-03 2018-04-17 Kohjin Life Sciences Co Ltd composição para aperfeiçoamento ou prevenção de uma doença de fígado gorduroso não alcoólico
JP2018524274A (ja) 2015-05-13 2018-08-30 ディーエス バイオファーマ リミテッド １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
IL300476B2 (en) * 2015-06-30 2024-07-01 Eiger Group Int Inc Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
WO2017109706A1 (en) * 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
MX394409B (es) * 2016-03-04 2025-03-24 Galectin Sciences Llc Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
FR3050112B1 (fr) 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
ES2966111T3 (es) * 2016-06-03 2024-04-18 Chemocentryx Inc Pirrolo-piridinas y pirrolo-pirimidinas para su uso en el tratamiento de la fibrosis hepática
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
CA3062648A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
WO2019010024A1 (en) * 2017-07-04 2019-01-10 The Regents Of The University Of California METHODS OF TREATING LIVER DISEASES ASSOCIATED WITH INFLAMMATION OF DOOR SPACE OR PERIODAL INFLAMMATION
CN111183360B (zh) * 2017-07-19 2024-10-18 生物辐射欧洲有限公司 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合
GB201804922D0 (en) * 2018-03-27 2018-05-09 Ucl Business Plc Traatment
JP2021529163A (ja) 2018-06-29 2021-10-28 グリコス バイオメディカル オーワイ コンジュゲート
WO2021123506A1 (en) 2019-12-18 2021-06-24 Glykos Biomedical Oy Stabile conjugate
BR112022022737A2 (pt) * 2020-05-22 2023-01-31 Durect Corp Tratamento de esteatose hepática não alcoólica (ehna)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4011285A1 (de) 1990-04-06 1991-10-10 Steigerwald Arzneimittelwerk Arzneimittel zur behandlung von hyperlipidaemie und/oder atherosklerose
US6297229B1 (en) 1994-11-14 2001-10-02 Mayo Foundation For Medical Education And Research Use of ursodeoxycholic acid to treat nonalcoholic steatohepatitis
US5760010A (en) 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US6180139B1 (en) 1998-12-04 2001-01-30 Viva America Marketing, Inc. Composition and method for treating nonalcoholic steatohepatitis
WO2000062076A1 (en) * 1999-04-13 2000-10-19 Hsu Daniel K Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
US6592910B1 (en) 1999-04-20 2003-07-15 Board Of Trustees, Southern Illinois University Methods of treating clinical diseases with isoflavones
CN1142272C (zh) 2000-02-02 2004-03-17 中国人民解放军军事医学科学院百环生物医学研究中心 携带人肝细胞生长因子基因的重组腺病毒的用途
CN100558407C (zh) * 2000-02-04 2009-11-11 柳署弘 制备含有胆汁酸的澄清水溶液剂型
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
BR0211336A (pt) 2001-07-20 2004-09-28 Intermune Inc Métodos para o tratamento da fibrose do fìgado
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
US7078064B2 (en) 2003-12-03 2006-07-18 George Zabrecky Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis
ATE555101T1 (de) 2004-02-27 2012-05-15 Asahi Kasei Pharma Corp Neue benzothiazepin- und benzothiepinverbindungen
CA2582428A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
JP2008105945A (ja) 2005-02-07 2008-05-08 Ajinomoto Co Inc アディポネクチンの分泌促進又は誘導作用を有するアシルアミド化合物
US7897583B2 (en) 2005-05-24 2011-03-01 Isis Pharmaceuticals, Inc. Compositions and their uses directed to PTPRU
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
ATE450526T1 (de) 2005-06-20 2009-12-15 Schering Corp Als antagonisten von histamin h3 geeignete piperidinderivate
US7897591B2 (en) * 2005-07-28 2011-03-01 Children's Medical Center Corporation Method of treating fatty liver disease
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
WO2008011216A2 (en) * 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
JP5105297B2 (ja) 2006-05-25 2012-12-26 味の素株式会社 Ｐｐａｒ活性調節剤
JP2009539885A (ja) 2006-06-13 2009-11-19 メルク フロスト カナダ リミテツド ステアロイルコエンザイムａデルタ−９デサチュラーゼの阻害剤としてのアザシクロペンタン誘導体
US20080194575A1 (en) * 2006-10-04 2008-08-14 Naiara Beraza Treatment for non-alcoholic-steatohepatitis
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
ES2417179T3 (es) 2007-11-30 2013-08-06 The Regents Of The University Of California Métodos para tratar la esteatohepatitis no alcohólica (EHNA) mediante productos basados en cisteamina
JP5302900B2 (ja) * 2008-01-31 2013-10-02 アステラス製薬株式会社 脂肪性肝疾患の治療用医薬組成物
WO2009118343A1 (en) 2008-03-27 2009-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for determining the occurrence of a liver disease in a subject
JPWO2009151116A1 (ja) 2008-06-13 2011-11-17 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
US20110313276A1 (en) * 2008-11-18 2011-12-22 Centre Hospitalier Universitaire D'angers Non-invasive in vitro method for quantifying liver lesions
JP2010229099A (ja) * 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
KR101968370B1 (ko) * 2011-12-28 2019-04-11 갈렉틴 테라퓨틱스, 인크. 인간 질환의 치료를 위한 신규 탄수화물 약물의 조성물

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160243152A1 (en) * 2013-09-19 2016-08-25 The Research Foundation For The State University Of New York Methods and materials for treating diabetes or liver steatosis
US11160825B2 (en) * 2013-09-19 2021-11-02 Research Foundation Of The State University Of New York Methods and materials for treating diabetes or liver steatosis
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US11253538B2 (en) 2015-03-27 2022-02-22 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US10695363B2 (en) 2017-04-14 2020-06-30 Gelesis Llc Compositions and methods for treating or preventing gut permeability-related disorders

Also Published As

Publication number Publication date
ES2869884T3 (es) 2021-10-26
IL231512B (en) 2019-02-28
EP2755480B1 (en) 2021-03-31
KR101974675B1 (ko) 2019-05-02
BR112014006220A2 (pt) 2017-04-11
JP6185473B2 (ja) 2017-08-23
US8658787B2 (en) 2014-02-25
MX360979B (es) 2018-11-22
IL231512A0 (en) 2014-04-30
KR20140107180A (ko) 2014-09-04
MX2014003213A (es) 2015-05-15
AU2012308491B2 (en) 2016-01-07
CA2848711A1 (en) 2013-03-21
AU2012308491A1 (en) 2014-04-03
EP2755480A1 (en) 2014-07-23
WO2013040324A1 (en) 2013-03-21
WO2013040316A1 (en) 2013-03-21
JP2014526513A (ja) 2014-10-06
EP2755480A4 (en) 2015-04-29
US20130171151A1 (en) 2013-07-04
CN103945695A (zh) 2014-07-23
CN103945695B (zh) 2018-04-17
CA2848711C (en) 2019-08-06

Similar Documents

Publication Publication Date Title
US20130259870A1 (en) Galactomannan polysaccharide composition for the treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
US20230000898A1 (en) Composition of novel carbohydrate drug for treatment of human diseases

Legal Events

Date Code Title Description
AS Assignment

Owner name: GALECTIN THERAPEUTICS, INC., GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TRABER, PETER G.;ZOMER, ELIEZER;KLYOSOV, ANATOLE A.;SIGNING DATES FROM 20130124 TO 20130204;REEL/FRAME:029774/0884

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION